Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Income (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Net Income for 9 consecutive years, with -$11.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income rose 50.73% to -$11.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$4.3 million, a 93.75% increase, with the full-year FY2025 number at -$5.3 million, up 92.3% from a year prior.
  • Net Income was -$11.2 million for Q4 2025 at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • In the past five years, Net Income ranged from a high of $29.0 million in Q2 2022 to a low of -$84.3 million in Q2 2021.
  • A 5-year average of -$25.3 million and a median of -$16.2 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: soared 134.44% in 2022, then tumbled 3814.01% in 2024.
  • Akebia Therapeutics' Net Income stood at -$70.4 million in 2021, then skyrocketed by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then crashed by 3814.01% to -$22.8 million in 2024, then soared by 50.73% to -$11.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Net Income are -$11.2 million (Q4 2025), $540000.0 (Q3 2025), and $247000.0 (Q2 2025).